Association study between gene expression and multiple phenotypes in omics applications of complex diseases

Yujia Li; Yusi Fang; Peng Liu; George C. Tseng

Home/Archive/arXiv

arXiv · 2112.05818

Association study between gene expression and multiple phenotypes in omics applications of complex diseases

Yujia Li·Yusi Fang·Peng Liu·George C. Tseng

View original source ↗Read source document ↗Export metadata ↓

Abstract

Studying phenotype-gene association can uncover mechanism of diseases and develop efficient treatments. In complex disease where multiple phenotypes are available and correlated, analyzing and interpreting associated genes for each phenotype respectively may decrease statistical power and lose intepretation due to not considering the correlation between phenotypes. The typical approaches are many global testing methods, such as multivariate analysis of variance (MANOVA), which tests the overall association between phenotypes and each gene, without considersing the heterogeneity among phenotypes. In this paper, we extend and evaluate two p-value combination methods, adaptive weighted Fisher's method (AFp) and adaptive Fisher's method (AFz), to tackle this problem, where AFp stands out as our final proposed method, based on extensive simulations and a real application. Our proposed AFp method has three advantages over traditional global testing methods. Firstly, it can consider the heterogeneity of phenotypes and determines which specific phenotypes a gene is associated with, using phenotype specific 0-1 weights. Secondly, AFp takes the p-values from the test of association of each phenotype as input, thus can accommodate different types of phenotypes (continuous, binary and count). Thirdly, we also apply bootstrapping to construct a variability index for the weight estimator of AFp and generate a co-membership matrix to categorize (cluster) genes based on their association-patterns for intuitive biological investigations. Through extensive simulations, AFp shows superior performance over global testing methods in terms of type I error control and statistical power, as well as higher accuracy of 0-1 weights estimation over AFz. A real omics application with transcriptomic and clinical data of complex lung diseases demonstrates insightful biological findings of AFp.

Explore related subjects

stat.ME

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Yujia Li, Yusi Fang, Peng Liu, George C. Tseng. 2021-12-10. Association study between gene expression and multiple phenotypes in omics applications of complex diseases. https://arxiv.org/abs/2112.05818

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Considerations for the Integration of Randomized Controlled Trials and Real-World Data

As clinical decision-making increasingly moves toward individualized and context-specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real-world data, grounded in explicit causal frameworks, offers a path toward evidence that is both internally credible and externally relevant. In this article, we describe distinct objectives for the integration of randomized controlled trials and real-world data and discuss how these objectives shape key design and analytic considerations, illustrating the resulting choices through example estimands. We highlight practical issues that commonly arise in applied settings, including data relevance and curation, cross-source comparability, estimand specification, and sensitivity analysis. We aim for this article to help readers evaluate and implement principled approaches to integrating randomized controlled trials and real-world data in ways that can support more reliable treatment recommendations while maintaining regulatory-grade evidentiary standards.

stat.ME↗

arXiv2026

Validity of MMRM-based hypothesis testing under missing-not-at-random mechanisms

In randomized clinical trials with longitudinal continuous outcomes, missing-not-at-random (MNAR) missingness often motivates conservative alternatives to mixed models for repeated measures (MMRM). Such caution is important for estimation, but estimation and testing need not require identical assumptions. Moreover, overly conservative primary analyses may reduce power, increase required sample size, and raise trial costs. We investigated the validity of MMRM-based testing under the global null of identical longitudinal outcome distributions across groups. Because valid testing minimally requires treatment-effect estimators to converge to the null under the null hypothesis, we investigated sufficient conditions for this property. We introduced a proportional observation condition requiring ratios of observation probabilities relative to a reference group, conditional on the full outcome vector, to be outcome-independent, and showed that, with arbitrary post-baseline visits and monotone missingness, this condition is sufficient for convergence to the null value. The condition allows observation to depend on unobserved outcomes and permits between-group differences in overall observation probabilities through outcome-independent dropout, making it clinically interpretable while accommodating outcome-dependent MNAR missingness. Synthetic and data-based bootstrap simulations showed negligible bias and empirical test sizes near 0.05, including nonmonotone missingness. Thus, MNAR missingness does not by itself imply that a more conservative primary testing procedure is required. This result does not justify treatment-effect estimation under alternatives, which still requires estimand-based interpretation and sensitivity analyses.

stat.ME↗

arXiv2026

Optimized variance estimation under interference and complex experimental designs

Unbiased and consistent variance estimators generally do not exist for design-based treatment effect estimators because experimenters never observe more than one potential outcome for any unit. The problem is exacerbated by interference and complex experimental designs. Experimenters must accept conservative variance estimators in these settings, but they can strive to minimize the conservativeness. In this paper, we show that the task of constructing a minimally conservative variance estimator can be interpreted as an optimization problem that aims to find the lowest estimable upper bound of the true variance given the experimenter's risk preferences and knowledge of the potential outcomes. We characterize the set of admissible bounds in the class of quadratic forms, and we demonstrate that the optimization problem is a convex program for many natural objectives. The resulting variance estimators are guaranteed to be conservative regardless of whether the background knowledge used to construct the bound is correct, but the estimators are less conservative if the provided information is reasonably accurate. Numerical results show that the resulting variance estimators can be considerably less conservative than existing estimators, allowing experimenters to draw more informative inferences about treatment effects.

stat.ME↗